Research - Amicus Therapeutics (FOLD), with a current market value of just $271 million, represents a high-risk, high reward play for investors willing to bet that the … Continue Reading
Premium: Read NowResearch - Orexigen Therapeutics (OREX) on Thursday reported second quarter results. We’re bullish on OREX in the near-term, but some revelations on the company’s conference call work against the … Continue Reading
Read NowResearch - Orexigen Therapeutics (OREX) has again dipped below $5.50, which we find attractive 6 weeks ahead of the September 11 PDUFA decision for NB32 (Contrave, naltrexone/bupropion), … Continue Reading
Read NowResearch - After the bell on Friday evening, AcelRx (ACRX) reported that the FDA has issued a Complete Response Letter (CRL) to the company’s new drug application for Zalviso (sufentanil … Continue Reading
Read NowResearch - OGXI is a speculative, micro-cap oncology company – now, essentially a call option with multiple shots on goal. $60 million in cash/equivalents provide a backdrop … Continue Reading
Premium: Read NowResearch - Investors are skittish again, and healthcare investors more than others. Here’s why. In the Fed’s semi-annual monetary policy report, which accompanied Chairwoman Janet Yellen’s testimony before … Continue Reading
Premium: Read NowResearch - This small biotech company has three trials reading out in the second half of this year. First up, a phase 3 pivotal sometime this quarter.
Premium: Read Now
